The renal urodilatin system: clinical implications

被引:65
作者
Forssmann, WG [1 ]
Meyer, M [1 ]
Forssmann, K [1 ]
机构
[1] IPF PharmaCeut GmbH, An Inst, Hannover Med Sch, D-30625 Hannover, Germany
关键词
antihypertensive /diuretic agents; blood pressure; heart failure; hormones; natriuretic peptide; renal function; vasoconstrition; /dilation;
D O I
10.1016/S0008-6363(01)00331-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A renal natriuretic peptide and the 'renal urodilatin system' were identified after the observation that immunoassayable ANP in urine may not be identical to the circulating cardiac hormone ANP, which is a peptide of 28 amino acids. Urodilatin (INN: Ularitide) is a natriuretic peptide isolated from human urine and belongs to the family of A-type natriuretic peptides. Urodilatin is differentially processed to a peptide of 32 amino acids from the same precursor as ANP. It is synthesized in kidney tubular cells and secreted luminally. After secretion from epithelial cells of the distal and/or connecting tubules, Urodilatin interacts downstream at distal segments of the nephron with luminally located receptors whereby it regulates Na+ and water reabsorption. Thus, the physiological function of the renal Urodilatin system can be described as a paracrine intrarenal regulator for Na+ and water homeostasis, considering Urodilatin as a real diuretic-natriuretic regulatory peptide. However, the regulation upon which the Urodilatin secretion depends is still not clear. Since Urodilatin has been discovered, a great number of pharmacological and clinical investigations have been carried out using Urodilatin as a drug for several indications. So far, clinical phase I and II studies for acute renal failure, congestive heart failure, and bronchial asthma have been pet-formed. (C) 2001 Elsevier Science BY. All rights reserved.
引用
收藏
页码:450 / 462
页数:13
相关论文
共 107 条
[61]   HEMODYNAMIC AND RENAL EFFECTS OF URODILATIN BOLUS INJECTIONS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].
KENTSCH, M ;
LUDWIG, D ;
DRUMMER, C ;
GERZER, R ;
MULLERESCH, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (10) :662-669
[62]   Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide [J].
Kiemer, AK ;
Vollmar, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) :13444-13451
[63]   cGMP-mediated inhibition of TNF-α production by the atrial natriuretic peptide in murine macrophages [J].
Kiemer, AK ;
Hartung, T ;
Vollmar, AM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :175-181
[64]   Long-term administration of atrial natriuretic peptide in patients with acute heart failure [J].
Kitashiro, S ;
Sugiura, T ;
Takayama, Y ;
Tsuka, Y ;
Izuoka, T ;
Tokunaga, S ;
Iwasaka, T .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 33 (06) :948-952
[65]   ATRIAL NATRIURETIC FACTOR INHIBITS ANGIOTENSIN-INDUCED, NOREPINEPHRINE-INDUCED, AND POTASSIUM-INDUCED VASCULAR CONTRACTILITY [J].
KLEINERT, HD ;
MAACK, T ;
ATLAS, SA ;
JANUSZEWICZ, A ;
SEALEY, JE ;
LARAGH, JH .
HYPERTENSION, 1984, 6 (02) :I143-I147
[66]   THE EFFECTS OF ACUTE ALTITUDE EXPOSURE IN SWISS HIGHLANDERS AND LOWLANDERS [J].
KOLLER, EA ;
LESNIEWSKA, B ;
BUHRER, A ;
BUB, A ;
KOHL, J .
EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY AND OCCUPATIONAL PHYSIOLOGY, 1993, 66 (02) :146-154
[67]  
KRAUSE A, 2001, UNPUB HUMAN NATRIURE
[68]  
KUTHE A, 2001, UNPUB EXPRESSION GUA
[69]  
LAWS HJ, 1995, BONE MARROW TRANSPL, V16, P307
[70]   COMPARISON OF BINDING AND CYCLIC-GMP ACCUMULATION BY ATRIAL NATRIURETIC PEPTIDES IN ENDOTHELIAL-CELLS [J].
LEITMAN, DC ;
MURAD, F .
BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 885 (01) :74-79